DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study to Evaluate the Efficacy and Tolerance of WR279,396 for Old World Cutaneous Leishmaniasis

Information source: U.S. Army Medical Research and Materiel Command
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Old World Cutaneous Leishmaniasis

Intervention: WR279 396 with Tegaderm Dressing (Drug); WR 279, 396 with Gauze and Tape Dressing (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: U.S. Army Medical Research and Materiel Command

Official(s) and/or principal investigator(s):
Afif Ben Salah,, MD, PhD, Principal Investigator, Affiliation: Institut Pasteur, Tunisia

Summary

This Phase 2 study is to determine whether WR279396 with occlusion (a polyurethane dressing) is more effective than WR279396 without occlusion for once daily treatment. Extensive objective and subjective local tolerance data will also be captured during this trial, as well as surrogate markers (parasite loads and aminoglycosides concentration in the deep dermis) that may help to determine the optimal number and duration of treatments. The results from this study will help determine the most practical treatment schedule and will answer questions that are crucial to improve the present treatment regimen with WR279396 which is twice a day for 20 days.

Clinical Details

Official title: Topical Treatment of Old World Cutaneous Leishmaniasis With WR279396 (Paromomycin/Gentamicin Ointment): Efficacy and Tolerance of a Regimen Using an Occlusive Polyurethane Dressing

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Change from baseline tolerance will be evaluated by local adverse reactions and by laboratory signs of systemic events.

Secondary outcome: Efficacy

Detailed description: Forty-eight patients (48) with Old World cutaneous leishmaniasis will be randomly allocated to WR279396 treatment once a day for 20 days with an optimized polyurethane dressing (occlusion) (24 patients), or without occlusion (24 patients). All patients will be rescued with the standard of care accepted in Tunisia, if the patient is not cured. The active

ingredients of WR279396 are two aminoglycosides - paromomycin sulphate (15%) and gentamicin

sulphate (0. 5%) - in a base (AQIC).

Each subject will be followed for clinical cure for 90 days after the initiation of treatment. Cure is defined as 100% reepithelialization without relapse by 3 months. Tolerance will be evaluated by local adverse reactions and by laboratory signs of systemic events. In addition to the clinical evaluation of the CL lesions, the following parameters/clinical healing surrogates will be investigated: 1. parasite load will be determined in superficial and deep lesional dermis samples at D0 and D10. The mean parasite reduction ratio (parasite load at D10/parasite load at D0) in each group will be compared; 2. aminoglycoside concentrations in superficial and deep infiltrated dermis in each group will be compared.

Eligibility

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: The study population will be selected from adults (18y) patients and children above 15y in Tunisia (Old World)

- Age: 15 - 75 years old

- Lesion character: each diameter (horizontal and vertical) of the lesion test must

measure 7 mm, the lesion must be primarily ulcerative (i. e., not verrucous or nodular) and located in a biopsy friendly site of the body

- Parasitological diagnosis: have cutaneous leishmaniasis proven parasitologically in

lesion selected for inclusion in study (lesion test).

- Informed consent: have given written informed consent to participate in the study:

(i. e. patient or legal representative). Exclusion Criteria:

- Drug intolerance: history of known or suspected hypersensitivity or idiosyncratic

reactions to aminoglycosides in the patient or immediate family members.

- Previous use of antileishmanial drugs (within 2 months) or present use of routinely

nephrotoxic or ototoxic drugs.

- Potential for follow up: Have less than 4 months time remaining in present address

and/or plans to leave the area for more than 30 days.

- Extent of disease: More than 10 lesions or lesion ³ 5 cm or a lesion less than 2 cm

from eye, in the ear, or a lesion in the face, that in the opinion of the attending dermatologist could potentially cause significant disfigurement.

- Location of disease: mucosal involvement.

- Disseminated disease: clinically significant lymphadenitis with nodules that are

painful and > 1 cm in size in the lymphatic drainage of the ulcer.

- Concomitant medical problems: significant medical problems of the kidney or liver as

determined by history and by the following laboratory studies:

- Kidney: clinically significant abnormalities of urine analysis, serum levels of

Creatinine, BUN, total proteins > upper limit of normal for the laboratory.

- Liver: AST or ALT > upper limit of normal for the laboratory.

- General: glucose, Na, K, > upper limit of normal or < lower limit of normal for the

laboratory. Volunteers in whom these normal laboratory values are exceeded by less than 25% will not be automatically excluded. These volunteers will be evaluated on the basis of history, physical, as well as laboratory values.

- Scheduled or ongoing pregnancy as determined clinical and biological criteria.

- Presence of signs or symptoms of peripheral neuropathy, myasthenia gravis or

neuromuscular block

Locations and Contacts

Institut Pasteur, Tunis, Tunisia
Additional Information

Starting date: October 2005
Last updated: March 15, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017